What is the brand name of cisatracurium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cisatracurium Brand Name

Cisatracurium is marketed under the brand name Nimbex® 1, 2, 3.

Key Information

Cisatracurium besylate is the generic name for this non-depolarizing neuromuscular blocking agent. The drug is available as:

  • Nimbex® (brand name, manufactured by Glaxo-Wellcome) 3
  • Various generic formulations (e.g., Cisatrex®) 2

Clinical Context

Cisatracurium is one of 10 stereoisomers of atracurium besylate and constitutes approximately 15% of the atracurium mixture 1. It is classified as an intermediate-acting benzylisoquinoline muscle relaxant with several advantageous properties:

  • Organ-independent elimination via Hofmann degradation, making it particularly suitable for patients with renal or hepatic failure 4
  • Higher potency than atracurium, resulting in lower doses and reduced laudanosine generation 4
  • Minimal histamine release and cardiovascular effects 3, 5

The FDA-approved formulation is supplied as Cisatracurium Besylate Injection, USP in concentrations of 2 mg/mL (for general use) and 10 mg/mL (for ICU use only) 1.

References

5
Research

The Use of Cisatracurium in Cardiac Surgery.

Turkish journal of anaesthesiology and reanimation, 2025

Related Questions

What is the recommended loading dose and infusion rate for initiating a cisatracurium infusion, and how should it be adjusted for elderly patients or those with organ dysfunction?
Can cisatracurium be used for neuromuscular paralysis in an intubated patient with serotonin syndrome who is developing increased peak airway pressures from severe muscle rigidity?
Can enteral nutrition be administered concurrently with Nimbex (cisatracurium) infusion?
What is the appropriate preparation and dosing regimen of cisatracurium for continuous infusion in adult mechanically ventilated patients?
Does atracurium cause tachycardia?
What muscle relaxant is appropriate for a patient with a glomerular filtration rate of 25 mL/min?
What should the treatment be for a patient with bilateral patellofemoral pain, lateral patellar tilt, an increased tibial tuberosity–trochlear groove distance of 22 mm, right‑knee trochlear dysplasia, no recent patellar dislocation, no focal patellofemoral chondrosis, and no acute fracture or joint effusion?
A patient with a healed finger laceration sustained two weeks ago now has decreased grip strength; what evaluation and management are recommended?
What are the perioperative management recommendations for a patient with hypokalemic periodic paralysis undergoing surgery?
When should a patient be referred to pain management in primary care?
What is the appropriate treatment for acute sinusitis in a 57-year-old female?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.